Press Release: Nurix : Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025
Read full article »
Nurix is a California-based biotechnology company that researches and develops small-molecule therapies for the treatment of cancer and immune disorders.
Read more